Type 1 Diabetes Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The type 1 diabetes market size has grown rapidly in recent years. It will grow from $11.82 billion in 2024 to $13.62 billion in 2025 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to growing demand for effective treatments, growing public awareness of type 1 diabetes, growing funds for drug development, incremental healthcare spending across the world.

The type 1 diabetes market size is expected to see rapid growth in the next few years. It will grow to $22.7 billion in 2029 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to growing awareness of early checkups for diabetes, growing adoption of home-care settings, increasing research for advanced drugs, increasing awareness of the consumption of nutritional products. Major trends in the forecast period include advanced insulin formulations, advancements in drugs and treatments, artificial pancreas systems, personalized medicine approaches.

The anticipated growth of the type 1 diabetes market is expected to be fueled by increasing government efforts to tackle diabetes. Government initiatives encompass a range of actions, policies, programs, or projects undertaken by governmental authorities to address specific issues, achieve objectives, or instigate positive changes in various aspects of society. Notably, government bodies are launching multiple initiatives aimed at combating diabetes, including type 1 diabetes. These initiatives are geared towards lowering diabetes risks and ensuring that all individuals diagnosed with diabetes have access to fair, comprehensive, affordable, and high-quality treatment and care. An illustrative example is the collaboration between the Canadian government and JDRF Canada, a non-profit organization based in Canada, which pledged $33 million in support of 12 research projects focused on the prevention, detection, management, and treatment of diabetes in July 2023. This funding will also aid the establishment of a national screening research consortium that will unite experts and individuals affected by diabetes to advance early-stage, pre-symptomatic type 1 diabetes screening in Canada. Consequently, the upsurge in government initiatives aimed at combatting diabetes is a driving force behind the growth of the type 1 diabetes market.

The rising prevalence of obesity and heart disease is expected to drive the growth of the type 1 diabetes market in the future. Obesity is a medical condition characterized by an unhealthy accumulation of excess body fat, while heart disease encompasses various conditions that impact the heart and blood vessels. Excess body weight heightens the risk of insulin resistance, which can result in elevated blood sugar levels and the onset of type 1 diabetes. Additionally, high blood sugar levels can harm blood vessels and nerves that regulate the heart and blood vessels, contributing to heart disease. For instance, in September 2024, the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, reported that from August 2021 to August 2023, the prevalence of severe obesity among adults was 9.4%. This rate was particularly high in the 20-39 age group at 9.5% and in the 40-59 age group at 12%, while only 6.6% of adults aged 60 and older were categorized as severely obese. Similarly, in September 2024, data published by the British Heart Foundation, a UK-based cardiovascular research charity, indicated that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, comprising around 4 million males and 3.6 million females living with these conditions. These diseases account for about 27% of all deaths in the UK, resulting in over 170,000 deaths annually, or approximately 480 deaths each day, which translates to one death every three minutes. Therefore, the increasing rates of obesity and heart disease are fueling the growth of the type 1 diabetes market.

Prominent companies operating within the type 1 diabetes sector are concentrating their efforts on the development of cutting-edge solutions, including technologies like SmartGuard, as part of their strategy to maintain their market position. SmartGuard is a technology designed to assist individuals with diabetes, particularly those who may have concerns about hypoglycemia or lack awareness of it. An illustrative case in point is Medtronic PLC, an Irish-based company specializing in medical technology, services, and solutions, which introduced the MiniMed 780G system featuring advanced SmartGuard technology in March 2022. This innovative product represents a next-generation closed-loop insulin pump system that streamlines the management of type 1 diabetes. The system automates the administration of basal insulin and correction boluses at five-minute intervals, helping diabetes patients better avoid both high and low blood sugar levels. Furthermore, this system enables patients to reduce glucose level fluctuations and maintain their levels within predetermined parameters, ultimately enhancing their quality of life and achieving improved clinical outcomes.

In March of 2023, the French pharmaceutical and healthcare company, Sanofi, completed the acquisition of Provention Bio Inc. for a total of $2.9 billion. This strategic move by Sanofi is intended to bolster its presence in the realm of immune-mediated diseases and disease-modifying therapies, particularly in areas with significant unmet medical needs. Additionally, Sanofi aims to leverage its expertise in diabetes to maximize the potential of transformative therapies. Provention Bio Inc., based in the United States, specializes in the production of biopharmaceutical products, with a focus on type 1 diabetes.

Major companies operating in the type 1 diabetes market are Johnson and Johnson Limited, Merck and Co. Inc., Sanofi-Aventis LLC., AstraZeneca PLC, Abbott Laboratories, Medtronic PLC, Eli Lilly and Co Ltd., Novo Nordisk A/S, Vertex Pharmaceuticals Incorporated, Dexcom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Adaptive Biotechnologies Corporation, Xeris Pharmaceuticals Inc., MannKind Corporation, Biocon Ltd., Virta Health Corp., Bigfoot Biomedical Inc., ViaCyte Inc., Beta Bionics Inc., Adocia SA, Senseonics Holdings Inc., Zealand Pharmaceuticals A/S, Sigilon Therapeutics Inc., Provention Bio Inc.

North America was the largest region in the type 1 diabetes market in 2024. The regions covered in type 1 diabetes report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the type 1 diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The type 1 diabetes market consists of sales of drugs used to treat type 1 diabetes such as autoimmune type 1 diabetes and idiopathic type 1 diabetes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Type 1 diabetes, also known as juvenile diabetes or insulin-dependent diabetes, is a chronic condition that disrupts the body's ability to regulate blood sugar levels. It is a result of the immune system mistakenly attacking the pancreas's beta cells, which are responsible for producing insulin.

The primary categories of medications for managing type 1 diabetes include rapid-acting insulin analogs, long-acting insulin analogs, premix insulin analogs, and others. Rapid-acting insulin analogs are synthetic forms of insulin engineered to have a faster onset, a more rapid peak effect, and a shorter duration of action compared to natural insulin. Various devices like insulin pumps, insulin pens, and blood glucose meters are employed for managing the condition. These devices are used by individuals of various age groups, both children and adults, and cater to different end-users, including hospitals, research institutes, and home care settings.

The type 1 diabetes market research report is one of a series of new reports that provides type 1 diabetes market statistics, including type 1 diabetes industry global market size, regional shares, competitors with a type 1 diabetes market share, detailed type 1 diabetes market segments, market trends and opportunities and any further data you may need to thrive in the type 1 diabetes industry. This type 1 diabetes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.